Aug 06th 2012 - Edison Investment Research today published a report on Epigenomics entitled "Building The US Customer Base". In summary, the report says:
Epigenomics’ investment case hinges on the outcome of a non-inferiority, head-to-head study comparing Epi proColon, a blood-based colorectal cancer (CRC) screening test, to faecal immunochemical tests (FIT). This clinical study is an integral part of the final module required for Epi proColon’s FDA PMA submission, expected to be completed in Q412. Epigenomics is building its US customer base by licensing Septin9 to Quest, ARUP, GD and now Companion Dx, for laboratory-developed tests (LDT) and Abbott for in vitro diagnostic (IVD) test kits; Qiagen and Sysmex have IVD options. Epi proColon and Epi proLung are already being marketed in the EU.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »